Analyst Price Targets — IMDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 1:48 pm | — | Lake Street | $12.00 | $5.33 | TheFly | Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street |
| November 11, 2025 9:51 am | Mike Matson | Needham | $9.00 | $6.80 | StreetInsider | Insight Molecular Diagnostics Inc. (IMDX) PT Raised to $9 at Needham |
| May 21, 2025 12:42 pm | Thomas Flaten | UBS | $8.00 | $3.07 | TheFly | OncoCyte price target raised to $8 from $5 at Lake Street |
| April 24, 2024 10:38 am | Mike Matson | Needham | $4.25 | $2.38 | StreetInsider | OncoCyte Corp (OCX) PT Raised to $4.25 at Needham |
| December 1, 2022 9:13 am | — | Lake Street | $10.00 | $9.44 | Benzinga | Lake Street Downgrades OncoCyte to Hold, Lowers Price Target to $0.5 |
| November 18, 2022 5:05 am | — | Piper Sandler | $10.00 | $8.52 | Benzinga | Piper Sandler Downgrades OncoCyte to Neutral, Lowers Price Target to $0.5 |
| August 17, 2022 9:42 pm | David Westenberg | Piper Sandler | $30.00 | $17.48 | TheFly | OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler |
| August 11, 2022 10:43 am | — | Lake Street | $60.00 | $19.27 | Benzinga | Lake Street Maintains Buy on OncoCyte, Lowers Price Target to $3 |
| August 11, 2022 5:31 am | — | Needham | $42.00 | $19.02 | Benzinga | Needham Maintains Buy on OncoCyte, Lowers Price Target to $2.1 |
| May 15, 2022 9:15 pm | David Westenberg | Piper Sandler | $28.00 | $22.60 | TheFly | OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler |
Latest News for IMDX
NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference taking place September 10th, 2026 in New York.
Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript
NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola University Medical Center), who will join Nick Ioannou, MD, MHA (iMDx VP Medical Affairs) and Josh Riggs (iMDx CEO), to discuss the Company's GraftAssure…
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMDX.
U.S. House Trading
No House trades found for IMDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.